News

Perspectum and Nuance Collaborate to Scale Access to AI-Enabled Integrated Digital Care Platforms to Improve Patient Care for Metabolic Disease

FDA awards Perspectum major grant for the qualification of its noninvasive diagnostic biomarker to reduce liver biopsy in drug trials

LiverMultiScan shown to be a cost-effective alternative to liver biopsies for monitoring patients with autoimmune hepatitis

FDA Grants Clearance to Perspectum’s CoverScan – A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan

LiverMultiScan® detected earlier stages of treatable disease in patients with autoimmune hepatitis to allow tailored treatment

LiverMultiScan® has achieved nationwide payer coverage for diagnosis and management of NAFLD and other established chronic liver diseases

First patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric study using Perspectum’s imaging technology to help predict disease progression and guide patient management

New meta-analysis finds Perspectum’s non-invasive MRI biomarker cT1 is an effective alternative to biopsy for identifying patients at high risk of liver disease progression

Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health